3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
5
Melanoma
4
Carcinoma, Renal Cell
4
Lymphoma, Follicular
3
Lymphoma
3
Sarcoma
2
Lymphoma, Non-Hodgkin
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Zollinger-Ellison Syndrome
1
Virus Diseases
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Philadelphia Chromosome
1
Multiple Myeloma
1
Meningeal Carcinomatosis
1
Lymphoproliferative Disorders
1
Lymphomatoid Granulomatosis
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Kidney Neoplasms
1
Influenza, Human
1
Gastrointestinal Cancer Metastatic
1
Epstein-Barr Virus Infections
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Carcinoma in Situ
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
3
Oncolytic Virotherapy
2
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
2
Bevacizumab
2
valrubicin
1
thymoglobulin
1
ledipasvir, sofosbuvir drug combination
1
hepatitis C immune globulin, human
1
halofantrine
1
VP-102
1
Therapies, Investigational
1
Tenofovir
1
Rituximab
1
Radiotherapy, Intensity-Modulated
1
Papillomavirus Vaccines
1
Nimorazole
1
Mitomycin
1
Lamivudine
1
Kidney Transplantation
1
Ipilimumab
1
Interferons
1
Influenza Vaccines
1
Immunoglobulin G
1
Imiquimod
1
Gemcitabine
1
Gels
1
Fluorescent Antibody Technique
1
Drug Therapy
1
Cyclophosphamide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Virus Diseases
×
Interferons
×
Clear all
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled